Alnylam Pharmaceuticals (ALNY) Could Be 39% Undervalued On Fresh ESC 2026 Data
Alnylam Pharmaceuticals (ALNY) is back in focus after new data at the European Society of Cardiology Congress 2026 highlighted RNA interference treatments for transthyretin amyloidosis and high risk hypertension, prompting fresh scrutiny of the stock.
At a share price of $266.11, Alnylam Pharmaceuticals has seen momentum pick up in the short term, with a 7 day share price return of 12.24% and a 30 day share price return of 21.40%. However, the year to date share price return is still down 33.50% and the 1 year total shareholder return is down 41.13%, while the 3 year and 5 year total shareholder returns of 32.11% and 40.39% point to a mixed longer term picture as investors reassess growth potential and risks in light of the ESC data and the broader RNAi pipeline.
See how Alnylam Pharmaceuticals fits into the wider RNA therapeutics story by comparing it with a hand picked 37 healthcare AI stocks that are also pushing the boundaries in data driven drug development.
After a sharp rebound from the lows, yet with 1 year returns still deeply in the red, Alnylam Pharmaceuticals now forces a closer look. Does the current valuation still offer a skewed risk reward in favour of new buyers, or not?
Most Popular Narrative: 38.8% Undervalued
Alnylam Pharmaceuticals last closed at $266.11 while the most followed narrative anchors on a fair value of $434.72, which implies a sizeable valuation gap built on detailed growth and profitability forecasts.
Advancements in Alnylam's pipeline (e.g., fast-tracked nucresiran for ATTR-CM, mivelsiran in Alzheimer's, new programs in diabetes and bleeding disorders) demonstrate increasing R&D efficiency and accelerate time to market, potentially driving future step-function increases in both revenue and operational leverage as more assets advance or launch.
Want to see why this fair value sits well above today’s price? The narrative leans on rapid earnings expansion, rising margins and a future profit multiple usually reserved for mature large caps. Curious which precise growth path needs to play out for $434.72 to hold up?
Result: Fair Value of $434.72 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors in Alnylam Pharmaceuticals still need to weigh risks around the company’s heavy dependence on the TTR franchise, as well as pressure on margins from rising royalty and pricing headwinds.
Find out about the key risks to this Alnylam Pharmaceuticals narrative.
Another View: Multiples Paint A Tougher Picture For Alnylam Pharmaceuticals
The story looks different when you step away from fair value estimates and focus on simple market ratios. Alnylam Pharmaceuticals trades on a P/E of 46x, compared with a fair ratio of 32.5x and a US Biotechs industry average of 17x, plus a 33.3x peer average. That suggests investors are already paying up for growth that analysts also flag as uncertain. If the market moves closer to the fair ratio instead, how much room is really left for upside on today’s price?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
After all this, does the current sentiment around Alnylam Pharmaceuticals feel justified to you, or stretched? Take a closer look at the underlying data, weigh the potential rewards and risks for yourself, and finish by checking the 3 key rewards.
Looking for more investment ideas beyond Alnylam Pharmaceuticals?
If Alnylam Pharmaceuticals has sharpened your thinking, do not stop here. Use the Simply Wall St screener to surface fresh stock ideas tailored to your style.
- Target potential upside by scanning a curated 47 high quality undervalued stocks that pair solid fundamentals with prices that some investors may view as out of sync with underlying strength.
- Protect your downside by focusing on a 81 resilient stocks with low risk scores that screens for resilient businesses with sturdier balance sheets and steadier risk profiles.
- Get ahead of the crowd by reviewing a 19 high quality undiscovered gems that highlights financially strong companies that many investors may not yet be watching closely.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com